{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:28:57Z","timestamp":1787239737680,"version":"build-2736575974"},"reference-count":116,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2019,12,21]],"date-time":"2019-12-21T00:00:00Z","timestamp":1576886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>The CXC chemokine receptor CXCR3 and its chemokines CXCL10, CXCL9, and CXCL11 are implicated in the pathogenesis of autoimmune diseases. Here, we review these chemokines in autoimmune thyroiditis (AT), Graves disease (GD), thyroid eye disease (TED), type 1 diabetes (T1D), and Addison\u2019s disease (AAD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Evidence Acquisition<\/jats:title>\n                    <jats:p>A PubMed review of the literature was conducted, searching for the above-mentioned chemokines in combination with AT, GD, TED, T1D, and AAD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Evidence Synthesis<\/jats:title>\n                    <jats:p>Thyroid follicular cells in AT and GD, retroorbital cells in TED (fibroblasts, preadipocytes, myoblasts), \u03b2 cells and islets in T1D, and adrenal cells in AAD respond to interferon-\u03b3 (IFN-\u03b3) stimulation producing large amounts of these chemokines. Furthermore, lymphocytes and peripheral blood mononuclear cells (PBMC) are in part responsible for the secreted Th1 chemokines. In AT, GD, TED, T1D, and AAD, the circulating levels of these chemokines have been shown to be high. Furthermore, these chemokines have been associated with the early phases of the autoimmune response in all the above-mentioned disorders. High levels of these chemokines have been associated also with the \u201cactive phase\u201d of the disease in GD, and also in TED. Other studies have shown an association with the severity of hypothyroidism in AD, of hyperthyroidism in GD, with severity of TED, or with fulminant T1D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The reviewed data have shown the importance of the Th1 immune response in different endocrine autoimmune diseases, and many studies have suggested that CXCR3 and its chemokines might be considered as potential targets of new drugs for the treatment of these disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgz289","type":"journal-article","created":{"date-parts":[[2019,12,21]],"date-time":"2019-12-21T09:27:31Z","timestamp":1576920451000},"page":"1046-1060","source":"Crossref","is-referenced-by-count":89,"title":["Th1 Chemokines in Autoimmune Endocrine Disorders"],"prefix":"10.1210","volume":"105","author":[{"given":"Poupak","family":"Fallahi","sequence":"first","affiliation":[{"name":"Department of Translational Research of New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Martina","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ragusa","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Ruffilli","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Elia","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Rosaria","family":"Paparo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5211-6342","authenticated-orcid":false,"given":"Alessandro","family":"Antonelli","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2019,12,21]]},"reference":[{"issue":"1\u20132","key":"2021122210134978700_CIT0001","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jneuroim.2008.04.022","article-title":"Chemokines and neuromodulation","volume":"198","author":"M\u00e9lik\u2013Parsadaniantz","year":"2008","journal-title":"J Neuroimmunol."},{"issue":"11","key":"2021122210134978700_CIT0002","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1084\/jem.20021897","article-title":"An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4","volume":"197","author":"Lasagni","year":"2003","journal-title":"J Exp Med."},{"issue":"6","key":"2021122210134978700_CIT0003","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood-2002-12-3945","article-title":"CXCR3-mediated chemotaxis of human T cells is regulated by a Gi- and phospholipase C-dependent pathway and not via activation of MEK\/p44\/p42 MAPK nor Akt\/PI-3 kinase","volume":"102","author":"Smit","year":"2003","journal-title":"Blood."},{"key":"2021122210134978700_CIT0004","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - A target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat Rev."},{"key":"2021122210134978700_CIT0005","first-page":"100196","article-title":"Chemokines in hyperthyroidism","volume":"16","author":"Ferrari","year":"2019","journal-title":"J Clin Transl Endocrinol."},{"issue":"3","key":"2021122210134978700_CIT0006","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.autrev.2013.10.010","article-title":"Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases","volume":"13","author":"Antonelli","year":"2014","journal-title":"Autoimmun Rev."},{"issue":"6","key":"2021122210134978700_CIT0007","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1055\/s-2008-1073153","article-title":"Chemokines and autoimmune thyroid diseases","volume":"40","author":"Liu","year":"2008","journal-title":"Horm Metab Res."},{"issue":"2","key":"2021122210134978700_CIT0008","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.autrev.2014.10.016","article-title":"Autoimmune thyroid disorders","volume":"14","author":"Antonelli","year":"2015","journal-title":"Autoimmun Rev."},{"issue":"2","key":"2021122210134978700_CIT0009","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.cyto.2011.04.022","article-title":"Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10","volume":"55","author":"Antonelli","year":"2011","journal-title":"Cytokine."},{"issue":"6","key":"2021122210134978700_CIT0010","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1210\/jc.2010-2905","article-title":"Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis","volume":"96","author":"Antonelli","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122210134978700_CIT0011","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.cyto.2008.01.002","article-title":"High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis","volume":"42","author":"Antonelli","year":"2008","journal-title":"Cytokine."},{"issue":"3","key":"2021122210134978700_CIT0012","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cyto.2010.01.009","article-title":"Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists","volume":"50","author":"Antonelli","year":"2010","journal-title":"Cytokine."},{"issue":"12","key":"2021122210134978700_CIT0013","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.autrev.2016.09.009","article-title":"The association of other autoimmune diseases in patients with autoimmune thyroiditis: review of the literature and report of a large series of patients","volume":"15","author":"Fallahi","year":"2016","journal-title":"Autoimmun Rev."},{"issue":"4","key":"2021122210134978700_CIT0014","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1089\/thy.2010.0103","article-title":"Urticaria and thyroid autoimmunity","volume":"21","author":"Bagnasco","year":"2011","journal-title":"Thyroid."},{"issue":"2","key":"2021122210134978700_CIT0015","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2265.2006.02447.x","article-title":"Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves\u2019 disease, and modulation by methimazole therapy","volume":"64","author":"Antonelli","year":"2006","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"2","key":"2021122210134978700_CIT0016","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.metabol.2010.02.002","article-title":"Cytokines (interferon-\u03b3 and tumor necrosis factor-\u03b1)-induced nuclear factor-\u03baB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone","volume":"60","author":"Antonelli","year":"2011","journal-title":"Metabolism."},{"issue":"1","key":"2021122210134978700_CIT0017","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cytogfr.2014.01.006","article-title":"CXCR3, CXCL10 and type 1 diabetes","volume":"25","author":"Antonelli","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"issue":"9","key":"2021122210134978700_CIT0018","first-page":"1809","article-title":"Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis","volume":"35","author":"Antonelli","year":"2008","journal-title":"J Rheumatol."},{"key":"2021122210134978700_CIT0019","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1749-6632.2009.04813.x","article-title":"CXCR3, inflammation, and autoimmune diseases","volume":"1173","author":"Lacotte","year":"2009","journal-title":"Ann N Y Acad Sci."},{"issue":"5","key":"2021122210134978700_CIT0020","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.autrev.2012.10.001","article-title":"The interaction between CXCL10 and cytokines in chronic inflammatory arthritis","volume":"12","author":"Lee","year":"2013","journal-title":"Autoimmun Rev."},{"key":"2021122210134978700_CIT0021","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/1465-9921-14-121","article-title":"Interferon-inducible chemokines reflect severity and progression in sarcoidosis","volume":"14","author":"Su","year":"2013","journal-title":"Respir Res."},{"issue":"7","key":"2021122210134978700_CIT0022","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/08916930802170401","article-title":"High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis","volume":"41","author":"Antonelli","year":"2008","journal-title":"Autoimmunity."},{"issue":"4","key":"2021122210134978700_CIT0023","first-page":"e305","article-title":"HCV-related autoimmune disorders in HCV chronic infection","volume":"164","author":"Ferrari","year":"2013","journal-title":"Clin Ter."},{"key":"2021122210134978700_CIT0024","doi-asserted-by":"crossref","first-page":"468107","DOI":"10.1155\/2012\/468107","article-title":"Cytokines and HCV-related disorders","volume":"2012","author":"Fallahi","year":"2012","journal-title":"Clin Dev Immunol."},{"issue":"1","key":"2021122210134978700_CIT0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1586\/1744666X.2015.997214","article-title":"Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection","volume":"11","author":"Zignego","year":"2015","journal-title":"Expert Rev Clin Immunol."},{"issue":"3","key":"2021122210134978700_CIT0026","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4254\/wjh.v7.i3.327","article-title":"Hepatitis C virus syndrome: a constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin\u2019s lymphoma, and cancer","volume":"7","author":"Ferri","year":"2015","journal-title":"World J Hepatol."},{"issue":"4","key":"2021122210134978700_CIT0027","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1677\/ERC-08-0337","article-title":"Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists","volume":"16","author":"Antonelli","year":"2009","journal-title":"Endocr Relat Cancer."},{"issue":"2","key":"2021122210134978700_CIT0028","article-title":"Regulatory B and T cell responses in patients with autoimmune thyroid disease and healthy controls","volume":"63","author":"Kristensen","year":"2016","journal-title":"Dan Med J."},{"key":"2021122210134978700_CIT0029","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cyto.2019.01.003","article-title":"Immunological aspects of autoimmune thyroid disease - Complex interplay between cells and cytokines","volume":"116","author":"Luty","year":"2019","journal-title":"Cytokine."},{"issue":"4","key":"2021122210134978700_CIT0030","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2265.2004.02085.x","article-title":"Cellular immune responses in autoimmune thyroid disease","volume":"61","author":"Weetman","year":"2004","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"10","key":"2021122210134978700_CIT0031","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1210\/jcem.86.10.7953","article-title":"Thyrocytes from autoimmune thyroid disorders produce the chemokines IP\u201310 and Mig and attract CXCR3+ lymphocytes","volume":"86","author":"Garc\u00eda\u2013L\u00f3pez","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021122210134978700_CIT0032","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.yexmp.2004.08.004","article-title":"Early chemokine expression induced by interferon-gamma in a murine model of Hashimoto\u2019s thyroiditis","volume":"77","author":"Kimura","year":"2004","journal-title":"Exp Mol Pathol."},{"issue":"11","key":"2021122210134978700_CIT0033","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1210\/jc.2004-0977","article-title":"High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism","volume":"89","author":"Antonelli","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2021122210134978700_CIT0034","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1055\/s-2008-1073151","article-title":"Circulating chemokines in patients with autoimmune thyroid diseases","volume":"40","author":"Domberg","year":"2008","journal-title":"Horm Metab Res."},{"issue":"12","key":"2021122210134978700_CIT0035","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1089\/jir.2012.0091","article-title":"Increased CXCL9 serum levels in hepatitis C-related mixed cryoglobulinemia, with autoimmune thyroiditis, associated with high levels of CXCL10","volume":"33","author":"Antonelli","year":"2013","journal-title":"J Interferon Cytokine Res."},{"issue":"2","key":"2021122210134978700_CIT0036","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/09513590.2013.871514","article-title":"Higher levels of circulating CXCL-9 and CXCL-11 in euthyroid women with autoimmune thyroiditis and recurrent spontaneous abortions","volume":"30","author":"Aktas","year":"2014","journal-title":"Gynecol Endocrinol."},{"issue":"5","key":"2021122210134978700_CIT0037","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3109\/08916934.2015.1134507","article-title":"Association of the polymorphisms of chemokine genes (IL8, RANTES, MIG, IP10, MCP1 and IL16) with the pathogenesis of autoimmune thyroid diseases","volume":"49","author":"Akahane","year":"2016","journal-title":"Autoimmunity."},{"issue":"6","key":"2021122210134978700_CIT0038","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1530\/EC-18-0019","article-title":"Aberrant MRP14 expression in thyroid follicular cells mediates chemokine secretion through the IL-1\u03b2\/MAPK pathway in Hashimoto\u2019s thyroiditis","volume":"7","author":"Luo","year":"2018","journal-title":"Endocr Connect."},{"issue":"6","key":"2021122210134978700_CIT0039","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/jir.2008.0090","article-title":"CXCL10 and CCL2 chemokine serum levels in patients with hepatitis C associated with autoimmune thyroiditis","volume":"29","author":"Antonelli","year":"2009","journal-title":"J Interferon Cytokine Res."},{"issue":"11","key":"2021122210134978700_CIT0040","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1089\/jir.2010.0024","article-title":"Interleukin-1\u03b2, C-x-C motif ligand 10, and interferon-gamma serum levels in mixed cryoglobulinemia with or without autoimmune thyroiditis","volume":"30","author":"Antonelli","year":"2010","journal-title":"J Interferon Cytokine Res."},{"issue":"16","key":"2021122210134978700_CIT0041","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 Disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med."},{"issue":"2","key":"2021122210134978700_CIT0042","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.autrev.2010.08.018","article-title":"Bioassays for TSH-receptor autoantibodies: an update","volume":"10","author":"Lytton","year":"2010","journal-title":"Autoimmun Rev."},{"issue":"1","key":"2021122210134978700_CIT0043","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0002-9440(10)64171-5","article-title":"Expression of IP-10\/CXCL10 and MIG\/CXCL9 in the thyroid and increased levels of IP-10\/CXCL10 in the serum of patients with recent-onset Graves\u2019 disease","volume":"161","author":"Romagnani","year":"2002","journal-title":"Am J Pathol."},{"issue":"2","key":"2021122210134978700_CIT0044","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1210\/jc.2005-1689","article-title":"Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves\u2019 ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists","volume":"91","author":"Antonelli","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2021122210134978700_CIT0045","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1210\/jc.2008-2450","article-title":"Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves\u2019 disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists","volume":"94","author":"Antonelli","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"key":"2021122210134978700_CIT0046","doi-asserted-by":"crossref","first-page":"232818","DOI":"10.1155\/2015\/232818","article-title":"Peroxisome proliferator-activated receptor- \u03b3 in thyroid autoimmunity","volume":"2015","author":"Ferrari","year":"2015","journal-title":"PPAR Res."},{"issue":"12","key":"2021122210134978700_CIT0047","doi-asserted-by":"crossref","first-page":"E413","DOI":"10.1210\/jc.2010-0923","article-title":"CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves\u2019 and normal thyrocytes","volume":"95","author":"Antonelli","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2021122210134978700_CIT0048","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.yexcr.2011.04.007","article-title":"Peroxisome proliferator-activated receptor \u03b1 agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves\u2019 disease","volume":"317","author":"Antonelli","year":"2011","journal-title":"Exp Cell Res."},{"issue":"11","key":"2021122210134978700_CIT0049","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1089\/thy.2012.0485","article-title":"Increase of interferon-\u03b3 inducible CXCL9 and CXCL11 serum levels in patients with active Graves\u2019 disease and modulation by methimazole therapy","volume":"23","author":"Antonelli","year":"2013","journal-title":"Thyroid."},{"issue":"10","key":"2021122210134978700_CIT0050","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1002\/bjs.5401","article-title":"Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves\u2019 disease, and modulation by methimazole therapy and thyroidectomy","volume":"93","author":"Antonelli","year":"2006","journal-title":"Br J Surg."},{"issue":"4","key":"2021122210134978700_CIT0051","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1210\/jc.2006-1571","article-title":"Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves\u2019 disease or toxic nodular goiter","volume":"92","author":"Antonelli","year":"2007","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021122210134978700_CIT0052","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1055\/s-0031-1271620","article-title":"Influence of methimazole and radioactive iodine treatment in the serum levels of the chemokine CXCL10 in hyperthyroid patients with Graves\u2019 disease","volume":"43","author":"Leite","year":"2011","journal-title":"Horm Metab Res."},{"issue":"13","key":"2021122210134978700_CIT0053","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1055\/s-0032-1316352","article-title":"Circulating CXCL9 and CXCL10 as markers of activity of Graves\u2019 orbitopathy during treatment with corticosteroids and teleradiotherapy","volume":"44","author":"Mysliwiec","year":"2012","journal-title":"Horm Metab Res."},{"issue":"11","key":"2021122210134978700_CIT0054","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.autrev.2014.08.025","article-title":"Extra-ocular muscle cells from patients with Graves\u2019 ophthalmopathy secrete \u03b1 (CXCL10) and \u03b2 (CCL2) chemokines under the influence of cytokines that are modulated by PPAR\u03b3","volume":"13","author":"Antonelli","year":"2014","journal-title":"Autoimmun Rev."},{"issue":"2","key":"2021122210134978700_CIT0055","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.mce.2011.11.001","article-title":"Peroxisome proliferator-activated receptor-\u03b1 agonists modulate CXCL9 and CXCL11 chemokines in Graves\u2019 ophthalmopathy fibroblasts and preadipocytes","volume":"349","author":"Antonelli","year":"2012","journal-title":"Mol Cell Endocrinol."},{"issue":"4","key":"2021122210134978700_CIT0056","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.autrev.2016.01.001","article-title":"The fire behind the disease","volume":"15","author":"Perricone","year":"2016","journal-title":"Autoimmun Rev."},{"issue":"10","key":"2021122210134978700_CIT0057","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1089\/105072502761016476","article-title":"Epidemiology and prevention of Graves\u2019 ophthalmopathy","volume":"12","author":"Wiersinga","year":"2002","journal-title":"Thyroid."},{"issue":"18","key":"2021122210134978700_CIT0058","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med."},{"issue":"2","key":"2021122210134978700_CIT0059","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41433-018-0279-9","article-title":"The involvement of T cell pathogenesis in thyroid-associated ophthalmopathy","volume":"33","author":"Huang","year":"2019","journal-title":"Eye (Lond)."},{"issue":"5","key":"2021122210134978700_CIT0060","doi-asserted-by":"crossref","first-page":"E262","DOI":"10.25011\/cim.v34i5.15668","article-title":"Short-term effect of radioactive iodine therapy on CXCL-10 production in Graves\u2019 disease","volume":"34","author":"Dong","year":"2011","journal-title":"Clin Invest Med."},{"key":"2021122210134978700_CIT0061","author":"Juvenile Diabetes Research Foundation."},{"issue":"5","key":"2021122210134978700_CIT0062","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/jcmm.12270","article-title":"Advances in the cellular immunological pathogenesis of type 1 diabetes","volume":"18","author":"Li","year":"2014","journal-title":"J Cell Mol Med."},{"issue":"1","key":"2021122210134978700_CIT0063","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S2213-8587(18)30112-8","article-title":"The challenge of modulating \u03b2-cell autoimmunity in type 1 diabetes","volume":"7","author":"Atkinson","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9","key":"2021122210134978700_CIT0064","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1007\/s00125-002-0886-6","article-title":"Autoimmunity to CD38 and GAD in Type I and Type II diabetes: CD38 and HLA genotypes and clinical phenotypes","volume":"45","author":"Antonelli","year":"2002","journal-title":"Diabetologia."},{"issue":"5","key":"2021122210134978700_CIT0065","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2337\/diabetes.50.5.985","article-title":"Human anti-CD38 autoantibodies raise intracellular calcium and stimulate insulin release in human pancreatic islets","volume":"50","author":"Antonelli","year":"2001","journal-title":"Diabetes."},{"issue":"6","key":"2021122210134978700_CIT0066","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.autrev.2005.12.001","article-title":"Dendritic cell subsets and type I diabetes: focus upon DC-based therapy","volume":"5","author":"Lo","year":"2006","journal-title":"Autoimmun Rev."},{"issue":"3","key":"2021122210134978700_CIT0067","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2337\/diacare.24.3.510","article-title":"Elevated serum IP-10 levels observed in type 1 diabetes","volume":"24","author":"Shimada","year":"2001","journal-title":"Diabetes Care."},{"issue":"8","key":"2021122210134978700_CIT0068","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s00125-002-0879-5","article-title":"Serum concentrations of the interferon-gamma-inducible chemokine IP-10\/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease","volume":"45","author":"Nicoletti","year":"2002","journal-title":"Diabetologia."},{"key":"2021122210134978700_CIT0069","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1196\/annals.1288.059","article-title":"Two cases of \u201cfulminant\u201d type 1 diabetes suggesting involvement of autoimmunity","volume":"1005","author":"Nakagawa","year":"2003","journal-title":"Ann N Y Acad Sci."},{"issue":"1","key":"2021122210134978700_CIT0070","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2249.2011.04538.x","article-title":"Serum titres of anti-glutamic acid decarboxylase-65 and anti-IA-2 autoantibodies are associated with different immunoregulatory milieu in newly diagnosed type 1 diabetes patients","volume":"168","author":"Gabbay","year":"2012","journal-title":"Clin Exp Immunol."},{"issue":"7","key":"2021122210134978700_CIT0071","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1007\/s00125-003-1134-4","article-title":"to: Nicoletti F, Conget L, Di Mauro M et al. (2002) Serum concentrations of the interferon\u2013alpha\u2013inducible chemokine IP\u201310\/CXCL10 are augmented in both newly\u2013diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease","volume":"46","author":"Rotondi","year":"2003","journal-title":"Diabetologia."},{"issue":"2","key":"2021122210134978700_CIT0072","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1464-5491.2005.01743.x","article-title":"Altered chemokine levels in individuals at risk of Type 1 diabetes mellitus","volume":"23","author":"Hanifi\u2013Moghaddam","year":"2006","journal-title":"Diabet Med."},{"issue":"11","key":"2021122210134978700_CIT0073","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/j.1464-5491.2008.02577.x","article-title":"Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed Type 1 diabetes: a longitudinal study","volume":"25","author":"Antonelli","year":"2008","journal-title":"Diabet Med."},{"issue":"5-6","key":"2021122210134978700_CIT0074","first-page":"531","article-title":"Increased circulating levels of CXC chemokines is correlated with duration and complications of the disease in type-1 diabetes: a study on Iranian diabetic patients","volume":"59","author":"Hakimizadeh","year":"2013","journal-title":"Clin Lab."},{"issue":"1","key":"2021122210134978700_CIT0075","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/dmrr.1052","article-title":"Ex vivo TCR-induced leukocyte gene expression of inflammatory mediators is increased in type 1 diabetic patients but not in overweight children","volume":"26","author":"Rosa","year":"2010","journal-title":"Diabetes Metab Res Rev."},{"issue":"3","key":"2021122210134978700_CIT0076","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2249.2009.04087.x","article-title":"Islet inflammation and CXCL10 in recent-onset type 1 diabetes","volume":"159","author":"Roep","year":"2010","journal-title":"Clin Exp Immunol."},{"issue":"11","key":"2021122210134978700_CIT0077","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1507\/endocrj.K10E-076","article-title":"Expression of chemokines, CXC chemokine ligand 10 (CXCL10) and CXCR3 in the inflamed islets of patients with recent-onset autoimmune type 1 diabetes","volume":"57","author":"Uno","year":"2010","journal-title":"Endocr J."},{"issue":"2","key":"2021122210134978700_CIT0078","doi-asserted-by":"crossref","first-page":"436","DOI":"10.2337\/db11-0853","article-title":"Expression and regulation of chemokines in murine and human type 1 diabetes","volume":"61","author":"Sarkar","year":"2012","journal-title":"Diabetes."},{"issue":"7","key":"2021122210134978700_CIT0079","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.humimm.2009.04.031","article-title":"Polymorphisms of CXCR3-binding chemokines in type 1 diabetes","volume":"70","author":"Br\u00fcck","year":"2009","journal-title":"Hum Immunol."},{"issue":"12","key":"2021122210134978700_CIT0080","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.imbio.2012.07.018","article-title":"1,25-Dihydroxyvitamin D3 curtails the inflammatory and T cell stimulatory capacity of macrophages through an IL-10-dependent mechanism","volume":"217","author":"Korf","year":"2012","journal-title":"Immunobiology."},{"issue":"4","key":"2021122210134978700_CIT0081","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s11033-013-3016-2","article-title":"RNA-seq methods for identifying differentially expressed gene in human pancreatic islet cells treated with pro-inflammatory cytokines","volume":"41","author":"Li","year":"2014","journal-title":"Mol Biol Rep."},{"issue":"1","key":"2021122210134978700_CIT0082","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00592-013-0518-2","article-title":"St. John\u2019s wort extract and hyperforin protect rat and human pancreatic islets against cytokine toxicity","volume":"51","author":"Novelli","year":"2014","journal-title":"Acta Diabetol."},{"issue":"5","key":"2021122210134978700_CIT0083","doi-asserted-by":"crossref","first-page":"e0126311","DOI":"10.1371\/journal.pone.0126311","article-title":"Th1-like icos+ foxp3+ treg cells preferentially express cxcr3 and home to \u03b2-islets during pre-diabetes in bdc2.5 nod mice","volume":"10","author":"Kornete","year":"2015","journal-title":"Plos One."},{"issue":"9","key":"2021122210134978700_CIT0084","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.humimm.2015.09.018","article-title":"Altered crosstalk in the dipeptidyl peptidase-4-incretin-immune system in type 1 diabetes: a hypothesis generating pilot study","volume":"76","author":"Z\u00f3ka","year":"2015","journal-title":"Hum Immunol."},{"issue":"6","key":"2021122210134978700_CIT0085","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/biof.1304","article-title":"Pancreatic \u03b2-Cell production of CXCR3 ligands precedes diabetes onset","volume":"42","author":"Burke","year":"2016","journal-title":"Biofactors."},{"issue":"12","key":"2021122210134978700_CIT0086","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1210\/jc.2018-00862","article-title":"Study of 2009 h1n1 pandemic influenza virus as a possible causative agent of diabetes","volume":"103","author":"Capua","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021122210134978700_CIT0087","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cmet.2018.09.011","article-title":"Lymphocyte-derived exosomal micrornas promote pancreatic \u03b2 cell death and may contribute to type 1 diabetes development","volume":"29","author":"Guay","year":"2019","journal-title":"Cell Metab."},{"issue":"1","key":"2021122210134978700_CIT0088","first-page":"48","article-title":"Altered chemokine Th1\/Th2 balance in Addison\u2019s disease: relationship with hydrocortisone dosing and quality of life","volume":"46","author":"Ekman","year":"2014","journal-title":"Horm Metab Res."},{"issue":"10","key":"2021122210134978700_CIT0089","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1210\/jc.2018-02672","article-title":"Unique inflammatory changes in exocrine and endocrine pancreas in enterovirus-induced fulminant type 1 diabetes","volume":"104","author":"Takita","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021122210134978700_CIT0090","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1210\/jc.2004-1062","article-title":"Elevated serum interferon-gamma-inducible chemokine-10\/CXC chemokine ligand-10 in autoimmune primary adrenal insufficiency and in vitro expression in human adrenal cells primary cultures after stimulation with proinflammatory cytokines","volume":"90","author":"Rotondi","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122210134978700_CIT0091","first-page":"9","article-title":"Update on autoimmune polyendocrine syndromes (APS)","volume":"74","author":"Betterle","year":"2003","journal-title":"Acta Biomed."},{"issue":"12","key":"2021122210134978700_CIT0092","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1210\/jc.2009-1115","article-title":"T cell responses to steroid cytochrome P450 21-hydroxylase in patients with autoimmune primary adrenal insufficiency","volume":"94","author":"Bratland","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2021122210134978700_CIT0093","first-page":"831","article-title":"Simultaneous evaluation of the circulating levels of both Th1 and Th2 chemokines in patients with autoimmune Addison\u2019s disease","volume":"34","author":"Bellastella","year":"2011","journal-title":"J Endocrinol Invest."},{"issue":"10","key":"2021122210134978700_CIT0094","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1089\/jir.2014.0171","article-title":"Peripheral blood cells from patients with autoimmune Addison\u2019s disease poorly respond to interferons in vitro, despite elevated serum levels of interferon-inducible chemokines","volume":"35","author":"Edvardsen","year":"2015","journal-title":"J Interferon Cytokine Res."},{"issue":"7","key":"2021122210134978700_CIT0095","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.4049\/jimmunol.167.7.4091","article-title":"Neutralization of the chemokine CXCL10 reduces inflammatory cell invasion and demyelination and improves neurological function in a viral model of multiple sclerosis","volume":"167","author":"Liu","year":"2001","journal-title":"J Immunol."},{"issue":"9","key":"2021122210134978700_CIT0096","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/01.MIB.0000178263.34099.89","article-title":"Anti-interferon-inducible chemokine, CXCL10, reduces colitis by impairing T helper-1 induction and recruitment in mice","volume":"11","author":"Hyun","year":"2005","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2021122210134978700_CIT0097","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1089\/jir.2007.0059","article-title":"CXCL10-producing mucosal CD4+ T cells, NK cells, and NKT cells are associated with chronic colitis in IL-10(-\/-) mice, which can be abrogated by anti-CXCL10 antibody inhibition","volume":"28","author":"Singh","year":"2008","journal-title":"J Interferon Cytokine Res."},{"issue":"3","key":"2021122210134978700_CIT0098","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/gutjnl-2012-303424","article-title":"Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study","volume":"63","author":"Mayer","year":"2014","journal-title":"Gut."},{"issue":"5","key":"2021122210134978700_CIT0099","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/hep4.1170","article-title":"NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid","volume":"2","author":"de Graaf","year":"2018","journal-title":"Hepatol Commun."},{"issue":"12","key":"2021122210134978700_CIT0100","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.4049\/jimmunol.179.12.8463","article-title":"Blockade of chemokine receptor CXCR3 inhibits T cell recruitment to inflamed joints and decreases the severity of adjuvant arthritis","volume":"179","author":"Mohan","year":"2007","journal-title":"J Immunol."},{"issue":"11","key":"2021122210134978700_CIT0101","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1002\/art.30573","article-title":"CXCL10 and its receptor CXCR3 regulate synovial fibroblast invasion in rheumatoid arthritis","volume":"63","author":"Laragione","year":"2011","journal-title":"Arthritis Rheum."},{"key":"2021122210134978700_CIT0102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2018.01.037","article-title":"JN-2, a C-X-C motif chemokine receptor 3 antagonist, ameliorates arthritis progression in an animal model","volume":"823","author":"Kim","year":"2018","journal-title":"Eur J Pharmacol."},{"key":"2021122210134978700_CIT0103","doi-asserted-by":"crossref","first-page":"109395","DOI":"10.1016\/j.cellsig.2019.109395","article-title":"CXCR3 antagonist AMG487 suppresses rheumatoid arthritis pathogenesis and progression by shifting the Th17\/Treg cell balance","volume":"64","author":"Bakheet","year":"2019","journal-title":"Cell Signal."},{"issue":"6","key":"2021122210134978700_CIT0104","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1002\/art.34330","article-title":"A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis","volume":"64","author":"Yellin","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"12","key":"2021122210134978700_CIT0105","doi-asserted-by":"crossref","first-page":"8401","DOI":"10.4049\/jimmunol.175.12.8401","article-title":"CXCL10 DNA vaccination prevents spontaneous diabetes through enhanced beta cell proliferation in NOD mice","volume":"175","author":"Shigihara","year":"2005","journal-title":"J Immunol."},{"issue":"3","key":"2021122210134978700_CIT0106","first-page":"209","article-title":"CXC chemokine ligand 10 DNA vaccination plus Complete Freund\u2019s Adjuvant reverses hyperglycemia in non-obese diabetic mice","volume":"7","author":"Oikawa","year":"2010","journal-title":"Rev Diabet Stud."},{"issue":"12","key":"2021122210134978700_CIT0107","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.2337\/db15-0479","article-title":"Anti-CD3\/Anti-Cxcl10 antibody combination therapy induces a persistent remission of type 1 diabetes in two mouse models","volume":"64","author":"Lasch","year":"2015","journal-title":"Diabetes."},{"issue":"1","key":"2021122210134978700_CIT0108","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2337\/db16-0547","article-title":"Islet-expressed CXCL10 promotes autoimmune destruction of islet isografts in mice with type 1 diabetes","volume":"66","author":"Bender","year":"2017","journal-title":"Diabetes."},{"issue":"7","key":"2021122210134978700_CIT0109","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.autrev.2019.05.004","article-title":"Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves\u2019 disease and ophthalmopathy","volume":"18","author":"Ferrari","year":"2019","journal-title":"Autoimmun Rev."},{"issue":"7","key":"2021122210134978700_CIT0110","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00251-013-0702-0","article-title":"PPARg2 Ala\u00b9\u00b2 variant protects against Graves\u2019 orbitopathy and modulates the course of the disease","volume":"65","author":"Pawlak-Adamska","year":"2013","journal-title":"Immunogenetics."},{"issue":"9","key":"2021122210134978700_CIT0111","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1089\/105072503322401032","article-title":"Peroxisome proliferator-activated receptor-gamma gene expression in orbital adipose\/connective tissues is increased during the active stage of Graves\u2019 ophthalmopathy","volume":"13","author":"Mimura","year":"2003","journal-title":"Thyroid."},{"key":"2021122210134978700_CIT0112","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2415-7-8","article-title":"Thiazolidinedione induced thyroid associated orbitopathy","volume":"7","author":"Lee","year":"2007","journal-title":"BMC Ophthalmol."},{"issue":"6","key":"2021122210134978700_CIT0113","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1210\/jc.2013-3919","article-title":"A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves\u2019 ophthalmopathy","volume":"99","author":"Zhu","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2021122210134978700_CIT0114","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1586\/17512433.2016.1157468","article-title":"Novel therapies for thyroid autoimmune diseases","volume":"9","author":"Fallahi","year":"2016","journal-title":"Expert Rev Clin Pharmacol."},{"issue":"7","key":"2021122210134978700_CIT0115","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1111\/bph.13027","article-title":"CXCR3 antagonist VUF10085 binds to an intrahelical site distinct from that of the broad spectrum antagonist TAK-779","volume":"172","author":"Nedjai","year":"2015","journal-title":"Br J Pharmacol."},{"issue":"3","key":"2021122210134978700_CIT0116","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.cytogfr.2014.11.009","article-title":"CXCR3 ligands in disease and therapy","volume":"26","author":"Van Raemdonck","year":"2015","journal-title":"Cytokine Growth Factor Rev."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgz289\/31584114\/dgz289.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/4\/1046\/41863359\/jcem_105_4_1046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/4\/1046\/41863359\/jcem_105_4_1046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T21:09:21Z","timestamp":1722200961000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/105\/4\/1046\/5683662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,21]]},"references-count":116,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,12,21]]},"published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgz289","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4]]},"published":{"date-parts":[[2019,12,21]]}}}